Emollients and moisturisers for eczema

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 3, 2016, Pages

  van Zuuren, Esther J ^a   Fedorowicz, Zbys ^b   Lavrijsen, Adriana ^a   Christensen, Robin ^c   Arents, Bernd ^d  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Bahrain Branch ^*  (Bahrain)

^c Mental Health Center Glostrup   (Denmark)

^d Dutch Association for People with Atopic Dermatitis   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIECZEMA AGENT; EMOLLIENT AGENT;

ADAPTIVE IMMUNITY; ATOPIC DERMATITIS; CONTACT DERMATITIS; DISEASE SEVERITY; ECZEMA; ENVIRONMENTAL FACTOR; HEALTH CARE PERSONNEL; HUMAN; LIKERT SCALE; META ANALYSIS; MOLECULAR WEIGHT; NUMMULAR DERMATITIS; PATIENT SATISFACTION; PERSONAL EXPERIENCE; PHYSICAL EXAMINATION; POMPHOLYX; PREVALENCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SENSITIVITY ANALYSIS; STRATUM CORNEUM; SYMPTOM ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 84961903083     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD012119     Document Type: Review

References (109)

1. Andersen RM, Thyssen JP, Maibach HI. Qualitative vs. quantitative atopic dermatitis criteria - in historical and present perspectives. Journal of the European Academy of Dermatology & Venereology 2015 Nov 4 [Epub ahead of print]. [PUBMED: 26538253]
2. Apfelbacher CJ, van Zuuren EJ, Fedorowicz Z, Jupiter A, Matterne U, Weisshaar E. Oral H1 antihistamines as monotherapy for eczema. Cochrane Database of Systematic Reviews 2013, Issue 2. [DOI: 10.1002/14651858.CD007770.pub2]
3. Ashcroft DM, Chen L-C, Garside R, Stein K, Williams HC. Topical pimecrolimus for eczema. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD005500.pub2]
4. Bamford JTM, Ray S, Musekiwa A, van Gool C, Humphreys R, Ernst E. Oral evening primrose oil and borage oil for eczema. Cochrane Database of Systematic Reviews 2013, Issue 4. [DOI: 10.1002/14651858.CD004416.pub2]
5. Bath-Hextall FJ, Delamere FM, Williams HC. Dietary exclusions for established atopic eczema. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD005203.pub2]
6. Bath-Hextall FJ, Birnie AJ, Ravenscroft JC, Williams HC. Interventions to reduce Staphylococcus aureus in the management of atopic eczema: an updated Cochrane review. British Journal of Dermatology 2010;163(1):12-26. [PUBMED: 20222931]
7. Bath-Hextall FJ, Jenkinson C, Humphreys R, Williams HC. Dietary supplements for established atopic eczema. Cochrane Database of Systematic Reviews 2012, Issue 2. [DOI: 10.1002/14651858.CD005205.pub3]
8. Bieber T. Atopic dermatitis. New England Journal of Medicine 2008;358(14):1483-94. [PUBMED: 18385500]
9. Birnie AJ, Bath-Hextall FJ, Ravenscroft JC, Williams HC. Interventions to reduce Staphylococcus aureus in the management of atopic eczema. Cochrane Database of Systematic Reviews 2002, Issue 4. [DOI: 10.1002/14651858.CD003871]
10. Boguniewicz M, Leung DYM. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunological Reviews 2011;242(1):233-46. [PUBMED: 21682749]
11. Bos JD, Brenninkmeijer EE, Schram ME, Middelkamp-Hup MA, Spuls PI, Smitt JH. Atopic eczema or atopiform dermatitis. Experimental Dermatology 2010;19(4):325-31. [PUBMED: 20100192]
12. Boyle RJ, Bath-Hextall FJ, Leonardi-Bee J, Murrell DF, Tang MLK. Probiotics for treating eczema. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD006135]
13. Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Statistics in Medicine 2007;26(1):53-77. [PUBMED: 16596572]
14. Calderon MA, Boyle RJ, Nankervis H, García Núñez I, Williams HC, Durham S. Specific allergen immunotherapy for the treatment of atopic eczema. Cochrane Database of Systematic Reviews 2010, Issue 10. [DOI: 10.1002/14651858.CD008774]
15. Caussin J, Gooris GS, Bouwstra JA. FTIR studies show lipophilic moisturizers to interact with stratum corneum lipids, rendering the more densely packed. Biochimica et Biophysica Acta 2008;1778(6):1517-24. [PUBMED: 18406341]
16. Caussin J. Skin, dry skin and moisturization. Doctoral thesis: Stratum corneum hydration : mode of action of moisturizers on a molecular level. Leiden: Division of Drug Delivery Technology (LACDR), Faculty of Science, Leiden University, 2009:7-21.
17. Caussin J, Rozema E, Gooris GS, Wiechers JW, Pavel S, Bouwstra JA. Hydrophilic and lipophilic moisturizers have similar penetration profiles but different effects on SC water distribution in vivo. Experimental Dermatology 2009;18(11):954-61. [PUBMED: 19555376]
18. Chamlin SL, Kao J, Frieden IJ, Sheu MY, Fowler AJ, Fluhr JW. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. Journal of the American Academy of Dermatology 2002;47(2):198-208. [PUBMED: 12140465]
19. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. British Journal of Dermatology 2000;142(5):931-6. [PUBMED: 10809850]
20. Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Archives of Dermatology 2004;140(12):1513-9. [PUBMED: 15611432]
21. Chung HJ, Jeon HS, Sung H, Kim MN, Hong SJ. Epidemiological characteristics of methicillin-resistant Staphylococcus aureus isolates from children with eczematous atopic dermatitis lesions. Journal of Clinical Microbiology 2008;46(3):991-5. [PUBMED: 18174298]
22. Cork MJ, Robinson DA, Vasilopoulos Y, Ferguson A, Moustafa M, MacGowan A, et al. New perspectives on epidermal barrier dysfunction in atopic dermatitis: gene-environment interactions. Journal of Allergy & Clinical Immunology 2006;118(1):3-21. [PUBMED: 16815133]
23. Cork MJ, Danby SG, Vasilopoulos Y, Hadgraft J, Lane ME, Moustafa M. Epidermal barrier dysfunction in atopic dermatitis. Journal of Investigative Dermatology 2009;129(8):1892-908. [PUBMED: 19494826]
24. Cury Martins J, Martins C, Aoki V, Gois AFT, Ishii HA, da Silva EMK. Topical tacrolimus for atopic dermatitis. Cochrane Database of Systematic Reviews 2015, Issue 7. [DOI: 10.1002/14651858.CD009864.pub2]
25. Deckers IA, McLean S, Linssen S, Mommers M, van Schayck CP, Sheikh A. Investigating international time trends in the incidence and prevalence of atopic eczema 1990-2010: a systematic review of epidemiological studies. PloS One 2012;7(7):e39803. [PUBMED: 22808063]
26. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88. [PUBMED: 3802833]
27. Dharmage SC, Lowe AJ, Matheson MC, Burgess JA, Allen KJ, Abramson MJ. Atopic dermatitis and the atopic march revisited. Allergy 2014;69(1):17-27. [PUBMED: 24117677]
28. Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. Journal of the American Academy of Dermatology 2014;70(2):338-51. [PUBMED: 24290431]
29. Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. Journal of the American Academy of Dermatology 2014;71(1):116-32. [PUBMED: 24813302]
30. Elias PM, Wakefield JS. Therapeutic implications of a barrier-based pathogenesis of atopic dermatitis. Clinical Reviews in Allergy & Immunology 2011;41(3):282-95. [PUBMED: 21174234]
31. Elias PM. Lipid abnormalities and lipid-based repair strategies in atopic dermatitis. Biochimica et Biophysica Acta 2014;1841(3):323-30. [PUBMED: 24128970]
32. Ersser SJ, Cowdell F, Latter S, Gardiner E, Flohr C, Thompson AR, et al. Psychological and educational interventions for atopic eczema in children. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD004054.pub3]
33. No authors listed. Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology 1993;186(1):23-31. [PUBMED: 8435513]
34. Flohr C, Johansson SG, Wahlgren CF, Williams H. How atopic is atopic dermatitis?. Journal of Allergy & Clinical Immunology 2004;114(1):150-8. [PUBMED: 15241359]
35. Flohr C, Weiland SK, Weinmayr G, Björkstén B, Bråbäck L, Brunekreef B, et al. The role of atopic sensitization in flexural eczema: findings from the International Study of Asthma and Allergies in Childhood Phase Two. Journal of Allergy & Clinical Immunology 2008;121(1):141-7. [PUBMED: 17980410]
36. Flohr C, Weinmayr G, Weiland SK, Addo-Yobo E, Annesi-Maesano I, Björkstén B, et al. How well do questionnaires perform compared with physical examination in detecting flexural eczema? Findings from the International Study of Asthma and Allergies in Childhood (ISAAC) Phase Two. British Journal of Dermatology 2009;161(4):846-53. [PUBMED: 19485999]
37. Flohr C, Mann J. New insights into the epidemiology of childhood atopic dermatitis. Allergy 2014;69(1):3-16. [PUBMED: 24417229]
38. Futamura M, Ferguson L, Vakirlis E, Kojima R, Roberts A, Mori R. Leukotriene receptor antagonists for atopic eczema. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD011224]
39. Ghadially R, Halkier-Sorensen L, Elias PM. Effects of petrolatum on stratum corneum structure and function. Journal of the American Academy of Dermatology 1992;26(3 Pt 2):387-96. [PUBMED: 1564142]
40. McMaster University, 2015 (developed by Evidence Prime, Inc.) Available from gradepro.org. GRADEpro Guideline Development Tool [Software]. McMaster University, 2015 (developed by Evidence Prime, Inc.) Available from gradepro.org, 2015.
41. Gu S, Yang AWH, Xue CCL, Li CG, Pang C, Zhang W, et al. Chinese herbal medicine for atopic eczema. Cochrane Database of Systematic Reviews 2013, Issue 9. [DOI: 10.1002/14651858.CD008642.pub2]
42. Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R. GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes. Journal of Clinical Epidemiology 2013;66(2):158-72. [PUBMED: 22609141]
43. Guyatt GH, Thorlund K, Oxman AD, Walter SD, Patrick D, Furukawa TA. GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes. Journal of Clinical Epidemiology 2013;66(2):173-83. [PUBMED: 23116689]
44. Haeck IM, Knol MJ, Ten Berge O, van Velsen SG, de Bruin-Weller MS, Bruijnzeel-Koomen CA. Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial. Journal of the American Academy of Dermatology 2011;64(6):1074-84. [PUBMED: 21458107]
45. Haileamlak A, Dagoye D, Williams H, Venn AJ, Hubbard R, Britton J, et al. Early life risk factors for atopic dermatitis in Ethiopian children. Journal of Allergy & Clinical Immunology 2005;115(2):370-6. [PUBMED: 15696097]
46. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Dermato-Venereologica 1980;92(Suppl):44-7.
47. Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Experimental Dermatology 2001;10(1):11-8. [PUBMED: 11168575]
48. Harcharik S, Emer J. Steroid-sparing properties of emollients in dermatology. Skin Therapy Letter 2014;19(1):5-10. [PUBMED: 2457029]
49. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
50. Hogewoning AA, Larbi IA, Addo HA, Amoah AS, Boakye D, Hartgers F, et al. Allergic characteristics of urban schoolchildren with atopic eczema in Ghana. Journal of the European Academy of Dermatology & Venereology 2010;24(12):1406-12. [PUBMED: 20456550]
51. Hogewoning AA, Bouwes Bavinck JN, Amoah AS, Boakye DA, Yazdanbakhsh M, Kremsner PG, et al. Point and period prevalences of eczema in rural and urban schoolchildren in Ghana, Gabon and Rwanda. Journal of the European Academy of Dermatology & Venereology 2012;26(4):488-94. [PUBMED: 21575064]
52. Jadotte YT, Santer M, Vakirlis E, Schwartz RA, Bauer A, Gundersen DA, et al. Complementary and alternative medicine treatments for atopic eczema. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD010938]
53. Janssens M, van Smeden J, Gooris GS, Bras W, Portale G, Caspers PJ, et al. Increase in short-chain ceramides correlates with an altered lipid organization and decreased barrier function in atopic eczema patients. Journal of Lipid Research 2012;53(12):2755-66. [PUBMED: 23024286]
54. Jenner N, Campbell J, Marks R. Morbidity and cost of atopic eczema in Australia. Australian Journal of Dermatology 2004;45(1):16-22. [PUBMED: 14961903]
55. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. Journal of Allergy & Clinical Immunology 2004;113(5):832-6. [PUBMED: 15131563]
56. Kezic S, Kemperman PM, Koster ES, de Jongh CM, Thio HB, Campbell LE, et al. Loss-of-function mutations in the filaggrin gene lead to reduced level of natural moisturizing factor in the stratum corneum. Journal of Investigative Dermatology 2008;128(8):2117-9. [PUBMED: 18305568]
57. Kunz B, Oranje AP, Labrèze L, Stalder JF, Ring J, Taïeb A. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1997;195(1):10-9. [PUBMED: 9267730]
58. Küster D, Spuls PI, Flohr C, Smith C, Hooft L, Deckert S, et al. Effects of systemic immunosuppressive therapies for moderate-to-severe eczema in children and adults. Cochrane Database of Systematic Reviews 2015, Issue 11. [DOI: 10.1002/14651858.CD011939]
59. Lee YL, Li CW, Sung FC, Yu HS, Sheu HM, Guo YL. Environmental factors, parental atopy and atopic eczema in primary-school children: a cross-sectional study in Taiwan. British Journal of Dermatology 2007;157(6):1217-24. [PUBMED: 17916197]
60. Leung DY. Atopic dermatitis: new insights and opportunities for therapeutic intervention. Journal of Allergy & Clinical Immunology 2000;105(5):860-76. [PUBMED: 10808164]
61. Lewis-Jones S. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. International Journal of Clinical Practice 2006;60(8):984-92. [PUBMED: 16893440]
62. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine 2009;6(7):e1000100. [PUBMED: 19621070]
63. Lodén M. Role of topical emollients and moisturizers in the treatment of dry skin barrier disorders. American Journal of Clinical Dermatology 2003;4(11):771-88. [PUBMED: 14572299]
64. Lodén M. Effect of moisturizers on epidermal barrier function. Clinics in Dermatology 2012;30(3):286-96. [PUBMED: 22507043]
65. Lucky AW, Leach AD, Laskarzewski P, Wenck H. Use of an emollient as a steroid-sparing agent in the treatment of mild to moderate atopic dermatitis in children. Pediatric Dermatology 1997;14(4):321-4. [PUBMED: 9263319]
66. Mack Correa MC, Nebus J. Management of patients with atopic dermatitis: the role of emollient therapy. Dermatology Research & Practice 2012;2012:836931. [PUBMED: 23008699]
67. Margolis JS, Abuabara K, Bilker W, Hoffstad O, Margolis DJ. Persistence of mild to moderate atopic dermatitis. Journal of the American Academy of Dermatology 2014;150(6):593-600. [PUBMED: 24696036]
68. Moed H, Yang Q, Oranje AP, Panda S, van der Wouden JC. Different strategies for using topical corticosteroids for established eczema. Cochrane Database of Systematic Reviews 2012, Issue 10. [DOI: 10.1002/14651858.CD010080]
69. Moncrieff G, Cork M, Lawton S, Kokiet S, Daly C, Clark C. Use of emollients in dry-skin conditions: consensus statement. Clinical & Experimental Dermatology 2013;38(3):231-8. [PUBMED: 23517354]
70. Msika P, De Belilovsky C, Piccardi N, Chebassier N, Baudouin C, Chadoutaud B. New emollient with topical corticosteroid-sparing effect in treatment of childhood atopic dermatitis: SCORAD and quality of life Improvement. Pediatric Dermatology 2008;25(6):606-12. [PUBMED: 19067864]
71. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380(9859):2197-223. [PUBMED: 23245608]
72. Möhrenschlager M, Darsow U, Schnopp C, Ring J. Atopic eczema: what's new?. Journal of the European Academy of Dermatology & Venereology 2006;20(5):503-11. [PUBMED: 16684275]
73. Nankervis H, Pynn EV, Boyle RJ, Rushton L, Williams HC, Hewson DM, et al. House dust mite reduction and avoidance measures for treating eczema. Cochrane Database of Systematic Reviews 2015, Issue 1. [DOI: 10.1002/14651858.CD008426.pub2]
74. National Institute for Health and Clinical Excellence (NICE). Atopic eczema in under 12s: diagnosis and management (CG57). www.nice.org.uk/guidance/cg57 2007.
75. Nutten S. Atopic dermatitis: global epidemiology and risk factors. Annals of Nutrition & Metabolism 2015;66(Suppl 1):8-16. [PUBMED: 25925336]
76. Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI, ISAAC Phase Three Study Group. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. Journal of Allergy & Clinical Immunology 2009;124(6):1251-8. [PUBMED: 20004783]
77. Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nature Genetics 2006;38(4):441-6. [PUBMED: 16550169]
78. Penzer R. Best practice in emollient therapy: a statement for health care professionals. Dermatological Nursing 2012;11(4):4-19.
79. Petry V, Lipnharski C, Bessa GR, Silveira VB, Weber MB. Prevalence of community-acquired methicillin-resistant Staphylococcus aureus and antibiotic resistance in patients with atopic dermatitis in Porto Alegre, Brazil. International Journal of Dermatology 2013;53(6):731-5. [PUBMED: 24168078]
80. Rawlings AV, Canestrari DA, Dobkowski B. Moisturizer technology versus clinical performance. Dermatologic Therapy 2004;17(Suppl 1):49-56. [PUBMED: 14728699]
81. Rawlings AV, Matts PJ. Stratum corneum moisturization at the molecular level: an update in relation to the dry skin cycle. Journal of Investigative Dermatology 2005;124(6):1099-110. [PUBMED: 15955083]
82. Rawlings AV. Molecular basis for stratum corneum maturation and moisturization. British Journal of Dermatology 2014;171(Suppl 3):19-28. [PUBMED: 25234174]
83. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
84. Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. Journal of the European Academy of Dermatology and Venereology 2012;26(8):1045-60. [PUBMED: 22805051]
85. Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C. Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. Journal of the European Academy of Dermatology & Venereology 2012;26(9):1176-93. [PUBMED: 22813359]
86. Sagiv AE, Marcus Y. The connection between in vitro water uptake and in vivo skin moisturization. Skin Research & Technology 2003;9(4):306-11. [PUBMED: 14641880]
87. Schmitt J, Langan S, Williams HC. What are the best outcome measurements for atopic eczema? A systematic review. Journal of Allergy & Clinical Immunology 2007;120(6):1389-98. [PUBMED: 17910890]
88. Schmitt J, Spuls PI, Thomas KS, Simpson E, Furue M, Deckert S, et al. The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. Journal of Allergy & Clinical Immunology 2014;134(4):800-7. [PUBMED: 25282560]
89. Schünemann H, Brozek J, Guyatt G, Oxman A, editors. GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. Available from www.guidelinedevelopment.org/handbook, The GRADE Working Group, 2013.
90. Sidbury R, Tom WL, Bergman JN, Cooper KD, Silverman RA, Berger TG. Guidelines of care for the management of atopic dermatitis: Section 4. Prevention of disease flares and use of adjunctive therapies and approaches. Journal of the American Academy of Dermatology 2014;71(6):1218-33. [PUBMED: 25264237]
91. Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, Bergman JN. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. Journal of the American Academy of Dermatology 2014;71(2):327-49. [PUBMED: 24813298]
92. Scottish Intercollegiate Guidelines Network (SIGN). Management of atopic eczema in primary care. SIGN publication no.125, 2011. www.sign.ac.uk/guidelines/fulltext/125/index.html (accessed 6 January 2016).
93. Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. Journal of Allergy & Clinical Immunology 2013;132(5):1132-8. [PUBMED: 24094544]
94. Simpson EL, Berry TM, Brown PA, Hanifin JM. A pilot study of emollient therapy for the primary prevention of atopic dermatitis. Journal of the American Academy of Dermatology 2010;63(4):587-93. [PUBMED: 20692725]
95. Simpson EL, Chalmers JR, Hanifin JM, Thomas KS, Cork MJ, McLean WH, et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. Journal of Allergy & Clinical Immunology 2014;134(4):818-23. [PUBMED: 25282563]
96. Stalder JF, Barbarot S, Wollenberg A, Holm EA, De Raeve L, Seidenari S, et al. Patient-Oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in Europe. Allergy 2011;66(8):1114-21. [PUBMED: 21414011]
97. Thomas KS, Stuart B, O'Leary CJ, Schmitt J, Paul C, Williams HC, et al. Validation of treatment escalation as a definition of atopic eczema flares. PLoS One 2015;10(4):e0124770. [PUBMED: 25897763]
98. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16. [PUBMED: 17555582]
99. van Smeden J, Janssens M, Kaye EC, Caspers PJ, Lavrijsen AP, Vreeken RJ, et al. The importance of free fatty acid chain length for the skin barrier function in atopic eczema patients. Experimental Dermatology 2014;23(1):45-52. [PUBMED: 24299153]
100. van Smeden J, Janssens M, Gooris GS, Bouwstra JA. The important role of stratum corneum lipids for the cutaneous barrier function. Biochimica et Biophysica Acta 2014;1841(3):295-313. [PUBMED: 24252189]
101. van Zuuren EJ, Apfelbacher CJ, Fedorowicz Z, Jupiter A, Matterne U, Weisshaar E. No high level evidence to support the use of oral H1 antihistamines as monotherapy for eczema: a summary of a Cochrane systematic review. Systematic Reviews 2014;13(3):25. [PUBMED: 24625301]
102. Wald A. Tests of statistical hypotheses concerning several parameters when the number of observations is large. Transactions of the American Mathematical Society 1943;54:426-82.
103. Weber TM, Samarin F, Babcock MJ, Filbry A, Rippke F. Steroid-free over-the-counter eczema skin care formulations reduce risk of flare, prolong time to flare, and reduce eczema symptoms in pediatric subjects with atopic dermatitis. Journal of Drugs in Dermatology 2015;14(5):478-85. [PUBMED: 25942666]
104. Weidinger S, Novak N. Atopic dermatitis. Lancet 2015 Sep 11 [Epub ahead of print]:S0140-6736(15)00149-X.
105. Williams HC, Burney PG, Hay RJ, Archer CB, Shipley MJ, Hunter JJ, et al. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. British Journal of Dermatology 1994;131(3):383-96. [PUBMED: 7918015]
106. Williams HC, Burney PG, Pembroke AC, Hay RJ. Validation of the U.K. diagnostic criteria for atopic dermatitis in a population setting. U.K. Diagnostic Criteria for Atopic Dermatitis Working Party. British Journal of Dermatology 1996;135(1):12-7. [PUBMED: 8776351]
107. Williams HC. Clinical practice. Atopic dermatitis. New England Journal of Medicine 2005;352(22):2314-24. [PUBMED: 15930422]
108. Williams H, Flohr C. How epidemiology has challenged 3 prevailing concepts about atopic dermatitis. Journal of Allergy & Clinical Immunology 2006;118(1):209-13. [PUBMED: 16815157]
109. Williams H, Stewart A, von Mutius E, Cookson W, Ross Anderson H, and the International Study of Asthma and Allergies in Childhood (ISAAC) Phase one and Three Study Groups. Is eczema really on the increase worldwide?. Journal of Allergy & Clinical Immunology 2008;121(4):947-54. [EMBASE: 2008158035]